Over the next 10-20 years, investment opportunities in the healthcare economy will be driven by an imperative to create and deploy business and technological solutions to the U.S. healthcare crisis. We believe that innovations necessary to bend the trend will be addressed by private venture-backed companies, which have long been at the forefront of the next generation of ideas. New solutions will require a focus on productivity and value for the healthcare dollar, both of which have long been overlooked in the healthcare industry.
Psilos is expert at identifying and investing in healthcare services, healthcare information technology and medical technology companies geared toward improving the competitiveness, quality, accountability and productivity of the healthcare economy. With three funds and over $580 million under management, we have deployed a consistent healthcare investment model since our founding. This has resulted in a markedly distinguished portfolio of companies and enabled us to deliver superior returns to our investors.
Psilos differentiates its investment approach in the following ways:
We believe our differentiated approach results in a portfolio of transformative healthcare companies run by superb entrepreneurs where we are able to contribute meaningfully to a successful outcome. Our healthcare investment returns to date, which consistently place us in the top quartile among our peers, demonstrate the efficacy of our approach.

Mauna Kea Technologies flagship product, Cellvizio®, is the world's smallest and most flexible microscope and the first system designed to provide live, real-time images of internal human tissues at the cellular level during endoscopic procedures of the pulmonary and gastrointestinal tracts. This advanced imaging technique, essentially an “optical biopsy,” helps physicians more effectively assess tissues of interest and differentiate normal versus abnormal tissues that may be indicative of cancer. This new imaging modality provides physicians the potential to enable earlier diagnosis of cancerous tissues and to reduce the number of unnecessarily invasive and expensive biopsies.